News
Ore Pharmaceuticals to Announce First Quarter 2008 Financial Results on April 25, 2008
GAITHERSBURG, Md.-(Business Wire)-April 18, 2008 - Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it will release first quarter 2008 financial results on Friday, April 25, 2008 at 6:00 a.m. Eastern Time, before the open of the U.S. financial markets.
The Company will hold a related conference call and webcast, scheduled for 10:00 a.m. Eastern Time on the same day, to discuss the financial results. The conference call will be open to investors, analysts, members of the media, and the general public.
Conference Call Details: -0- *T Dial-In: 866.770.7051 Domestic 617.213.8064 International Passcode: 39203680 Replay Dial-In: 888.286.8010 Domestic 617.801.6888 International Passcode: 93000915 Available through May 9, 2008 Webcast: Please go to http://www.orepharma.com/investors/confcalls.cfm within 15 minutes prior to the call and select the webcast link. An archived webcast of the conference call will also be available under the Investors section of the Company's website at www.orepharma.com. *T
Ore Pharmaceuticals Overview
Ore Pharmaceuticals is a leading drug repositioning and development company. We apply our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We do this in two ways: We identify uses for stalled or failed drug compounds provided by our pharmaceutical partners, and, for our own pipeline, we identify new uses for drug compounds available in the public domain. Our own pipeline may also include compounds that our pharmaceutical partners decide not to develop for new uses we identify. We currently have one compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat inflammatory bowel disease (IBD, including ulcerative colitis and Crohn's disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. Visit us at orepharma.com or call 1-877-ORE-PHRM.
Search Our News Using Google Search
Can't find what you want? Try using Google:
